Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Andrew Zhu joins Chemokine's clinical advisory board

This article was originally published in Scrip

Executive Summary

Chemokine Therapeutics, a Canadian biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, has appointed Dr Andrew Zhuto its oncology clinical advisory board. Dr Zhu is an attending oncologist and the director of liver cancer research at Massachusetts General Hospital Cancer Center. He is also a staff physician at Dana-Farber Cancer Institute, and a member of Dana-Farber Harvard Cancer Center in Boston, Massachusetts.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC000047

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel